Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Newsletter 11/2026 March 15, 2026
- Blood Lipid Profiles in Metastatic Prostate Cancer: A Window into Tumor Metabolism and Response to Enzalutamide March 14, 2026
- Organoids from Routine TUR‑P Samples: A Personalized Platform for Prostate Cancer Therapy Testing March 13, 2026
- Estrogen‑Based Androgen Suppression Plus ARSI in Prostate Cancer: A Phase 2 Quality‑of‑Life Trial March 13, 2026
FG-3246 Advances to Phase 2 Trial in Prostate Cancer After Promising Early Results
/in Clinical Trial, Metastatic, Phase 2/by MaxMacrophage-Drug Conjugates: A New Frontier in Cancer Treatment
/in Delivery, Preclinical Research/by MaxAndrogen Receptor Inhibition Enhances Immune Response in Prostate Cancer
/in Immunotherapy, Preclinical Research/by MaxThe Phase 1 ACCEL Trial: Actinium-225-PSMA-62
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 3 Trial of TLX591 Kicks Off in Miami
/in Clinical Trial, Metastatic, Phase 3/by MaxCancer Vaccine? Yes, Universal Please…
/in Immunotherapy, Preclinical Research/by MaxGoogle’s AI Co-Scientist: A Leap Forward in Biomedical Research
/in Artificial Intelligence/by MaxOncoACP3: A Potential Game-Changer in Prostate Cancer Theranostics —Why?
/in Clinical Trial, Metastatic, Phase 1/by Max